CXCL9 and cancer: Extending from findings in melanoma, we demonstrate that oncogenic mutations that constitutively activate GNAS repress CXCL9/10/11 expression to dampen antitumor T cell response across human cancer types, including ICB-refractory pancreatic and liver cancers.